Form 4: Nephros Director Acquires Shares, Details Option Vesting

Lisa Marie Nettis, a Director at Nephros Inc., reported the acquisition of 1,622 shares of common stock and provided details on her existing stock options.

Summary

• Lisa Marie Nettis, a Director of Nephros Inc. (NEPH), acquired 1,622 shares of common stock on November 10, 2025, at a price of $0 per share.
• Following this transaction, Nettis beneficially owns 1,622 shares of common stock directly.
• The filing also details existing stock options to buy 13,229 shares of common stock at an exercise price of $4.49, expiring on August 11, 2035.
• These stock options vest in three tranches: 4,410 shares on June 16, 2025, 4,410 shares on June 16, 2026, and 4,409 options on June 16, 2027.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The filing is a neutral, routine disclosure of an insider's equity transactions, reflecting standard compensation practices rather than significant operational or financial news.

Positives

• A director's acquisition of shares, even at a $0 price (likely a grant), can signal continued alignment of interests with shareholders.
• The existence of a Rule 10b5-1 plan indicates a pre-planned, systematic approach to insider transactions, reducing concerns about opportunistic trading.

Negatives

• No specific negative points are identified in this routine insider transaction report.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance, beyond the scheduled vesting of stock options.

Industry Context

This filing is a routine disclosure of an insider transaction, common across all industries for publicly traded companies, and does not provide specific industry-related insights or trends.

Related Party Transactions

• The acquisition of shares and the holding of stock options by Lisa Marie Nettis, a Director, constitute related party transactions as they involve an insider of the company.

Stakeholder Impact

• Shareholders: The director's acquisition of shares aligns her interests with those of other shareholders, potentially signaling confidence in the company's future.
• Management/Employees: The equity grant and vesting schedule are part of the compensation structure designed to incentivize long-term performance.

Next Steps

• The vesting of 4,410 stock options is scheduled for June 16, 2025.
• The vesting of 4,410 stock options is scheduled for June 16, 2026.
• The vesting of 4,409 stock options is scheduled for June 16, 2027.

Key Dates

Keywords

Nephros Inc., NEPH, Form 4, Insider Transaction, Stock Acquisition, Stock Options, Director, Equity Grant, Rule 10b5-1